Response prediction - Early response evaluation: Consequences for surgical oncology;Response-vorhersage - Frühe Response-evaluation: Konsequenzen für die Chirurgische Onkologie

Chirurg

Volumn 77, Issue 12, 2006, Pages 1095-1103

  Siewert, J R ^a   Lordick, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemoradiation; Chemotherapy; Neoadjuvant; Prognosis; Response

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL TUMOR; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845370945     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-006-1270-8     Document Type: Review

References (57)

1. Amthauer H, Denecke T, Rau B et al. (2004) Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31:811-819
2. Brucher BL, Becker K, Lordick F et al. (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 15: 2119-2127
3. Brucher BL, Weber W, Bauer M et al. (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300-309
4. Casali PG, Garrett CR, Blackstein ME et al. (2006) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Cli Oncol ASCO Ann Meet Proc Part 124:9513 (abstract)
5. Cunningham D, Allum WH, StenningSPetal., MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
6. Debiec-Rychter M, Dumez H, Judson I et al., EORTC Soft Tissue and Bone Sarcoma Group (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer 40:689-695
7. DeneckeT, Rau B, Hoffmann KT et al. (2005) Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 15:1658-1666
8. Fletcher CD, Berman JJ, Corless C et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465
9. Gayed I, Vu T, lyer R et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17-21
10. Ghadimi BM, Grade M, Difilippantonio MJ et al. (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826-1838
11. Glynne-Jones R, Grainger J, Harrison M et al. (2006) Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 94:363-371
12. Grothey A, Sargent D (2005) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23: 9441-9442
13. Guillem JG, Chessin DB, Shia J et al. (2005) Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol 23:3475-3479
14. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KITpositive malignancies. J Clin Oncol 20:1692-1703
15. Heinrich MC, Corless CL, Blanke CD et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774
16. Heinrich MC, Corless CL, Demetri GD et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
17. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484-495
18. Hofheinz RD, Horisberger K, Woernle C et al. (2006) Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys Sep 15 [Epub ahead of print]
19. Hofheinz RD,von Gerstenberg-Helldorf B, Wenz F et al. (2005) Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350-1357
20. Ilson DH, Bains M, Rizk N et al. (2006) Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure. J Clin Oncol ASCO Ann Meeting Proc 24(185): 4023 (abstract)
21. Jakob C, Aust DE, Meyer W et al. (2004) Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neoadjuvant chemoradiotherapy in rectal cancer. J Pathol 204:562-568
22. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
23. Kalff V, Duong C, Drummond EG et al. (2006) Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 47:14-22
24. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646
25. Liersch T, Langer C, Ghadimi BM et al. (2006) Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24:4062-4068
26. Lordick F (2005) Neoadjuvant therapy for squamous cell carcinoma of the esophagus. Chirurg 76: 1025-1032
27. Lordick F, Ott K, Weber W et al. (2006) Response to neoadjuvant chemotherapy and the pattern of recurrence in locally advanced Barrett's cancer. Analysis from the MUNICON trial. Ann Oncol 17 (Suppl 6): 21 (abstract 0-009)
28. Lordick F, Peschel C, Siewert JR (2005) Antibody-based targeted therapy for gastric cancer. Gastric Cancer 8:206-208
29. Lordick F, Siewert JR (2005) Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 8:78-85
30. Luthra R, Wu TT, Luthra MG et al. (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24:259-267
31. Maki RG, Fletcher JA, Heinrich CM et al. (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol ASCO Ann Meet Proc Vol 23, 16S, Part 1:9011 (abstract)
32. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727-1733.
33. Metzger R, Leichman CG, Danenberg KD et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316
34. Napieralski R, Ott K, Kremer M et al. (2005) Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11:3025-3031
35. Ott K, Fink U, Becker K et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604-4610
36. Ott K, Vogelsang H, Marton N et al. (2006) The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer Aug 23 [Epub ahead of print]
37. Ott K, Vogelsang H, Mueller J et al. (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307-2315
38. Ott K, Weber WA, Lordick F et al. (2006) Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction. J Clin Oncol 24:4692-4698
39. Raut CP, Posner M, Desai J et al. (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325-2331
40. Rodel C, Grabenbauer GG, Papadopoulos T et al. (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21: 3098-3104
41. Rodel C, Liersch T, Hermann RM et al. (2006) Multicenter Phase II Trial of the German Rectal Cancer Study Group: Preoperative radiation with concomitant and adjuvant capecitabine and oxaliplatin for rectal cancer. J Clin Oncol: (accepted for publication)
42. Rodel C, Martus P, Papadoupolos T et al. (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688-8696
43. Rodel F, Hoffmann J, Distel L et al. (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881-4887
44. Rohatgi PR, Mansfield PF, Crane CH et al. (2006) Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107:1475-1482
45. Sauer R, Becker H, Hohenberger W et al., German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
46. Schuhmacher CP, Fink U, Becker K et al. (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918-927
47. Siewert JR, Lordick F, Ott K et al. (2006) Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies. Chirurg 77:227-235
48. Singer S, Rubin BP, Lux ML et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898-3905
49. Stahl A, Ott K, Weber WA et al. (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295
50. Stahl M, Stuschke M, Lehmann N et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317
51. Stipa F, Chessin DB, Shia J et al. (2006) A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 13:1047-1053
52. Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134
53. Weber WA, Ott K, Becker K et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065
54. Westerterp M, van Westreenen HL, Reitsma JB et al. (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 236: 841-851
55. Wieder HA, Beer AJ, Lordick F et al. (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029-2034
56. Wieder HA, Brucher BL, Zimmermann F et al. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900-908
57. Wu X, Gu J, Wu TT et al. (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789-3798